242 related articles for article (PubMed ID: 20546955)
1. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development.
Abdulahad DA; Westra J; Limburg PC; Kallenberg CG; Bijl M
Autoimmun Rev; 2010 Aug; 9(10):661-5. PubMed ID: 20546955
[TBL] [Abstract][Full Text] [Related]
2. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
3. The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus.
Yu SL; Wong CK; Tam LS
Expert Rev Clin Immunol; 2013 Aug; 9(8):739-49. PubMed ID: 23971752
[TBL] [Abstract][Full Text] [Related]
4. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
5. HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response.
Lu M; Yu S; Xu W; Gao B; Xiong S
J Immunol Res; 2015; 2015():946748. PubMed ID: 26078984
[TBL] [Abstract][Full Text] [Related]
6. High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE).
Abdulahad DA; Westra J; Reefman E; Zuidersma E; Bijzet J; Limburg PC; Kallenberg CG; Bijl M
Lupus; 2013 May; 22(6):597-606. PubMed ID: 23549344
[TBL] [Abstract][Full Text] [Related]
7. Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.
Yu SL; Wong CK; Szeto CC; Li EK; Cai Z; Tam LS
Lupus; 2015 Jun; 24(7):675-86. PubMed ID: 25411258
[TBL] [Abstract][Full Text] [Related]
8. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.
Urbonaviciute V; Fürnrohr BG; Meister S; Munoz L; Heyder P; De Marchis F; Bianchi ME; Kirschning C; Wagner H; Manfredi AA; Kalden JR; Schett G; Rovere-Querini P; Herrmann M; Voll RE
J Exp Med; 2008 Dec; 205(13):3007-18. PubMed ID: 19064698
[TBL] [Abstract][Full Text] [Related]
9. Anti-high mobility group box 1 (anti-HMGB1) antibodies are not related to the occurrence of cutaneous lesions in systemic lupus erythematosus.
Tan G; Zhu N; Shi Z; Meng Z; Yu M; Li K; Yin J; Wei K; Mi X; Wang L
Scand J Rheumatol; 2015; 44(2):150-6. PubMed ID: 25439526
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus.
Schaper F; Westra J; Bijl M
Mol Med; 2014 Mar; 20(1):72-9. PubMed ID: 24531837
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.
Qing X; Pitashny M; Thomas DB; Barrat FJ; Hogarth MP; Putterman C
Immunol Lett; 2008 Nov; 121(1):61-73. PubMed ID: 18822317
[TBL] [Abstract][Full Text] [Related]
12. High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases.
Voll RE; Urbonaviciute V; Herrmann M; Kalden JR
Isr Med Assoc J; 2008 Jan; 10(1):26-8. PubMed ID: 18300566
[TBL] [Abstract][Full Text] [Related]
13. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi.
Ahrens I; Chen YC; Topcic D; Bode M; Haenel D; Hagemeyer CE; Seeba H; Duerschmied D; Bassler N; Jandeleit-Dahm KA; Sweet MJ; Agrotis A; Bobik A; Peter K
Thromb Haemost; 2015 Nov; 114(5):994-1003. PubMed ID: 26202300
[TBL] [Abstract][Full Text] [Related]
14. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.
Musumeci D; Roviello GN; Montesarchio D
Pharmacol Ther; 2014 Mar; 141(3):347-57. PubMed ID: 24220159
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.
Tian J; Avalos AM; Mao SY; Chen B; Senthil K; Wu H; Parroche P; Drabic S; Golenbock D; Sirois C; Hua J; An LL; Audoly L; La Rosa G; Bierhaus A; Naworth P; Marshak-Rothstein A; Crow MK; Fitzgerald KA; Latz E; Kiener PA; Coyle AJ
Nat Immunol; 2007 May; 8(5):487-96. PubMed ID: 17417641
[TBL] [Abstract][Full Text] [Related]
16. High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus.
Pan HF; Wu GC; Li WP; Li XP; Ye DQ
Mol Biol Rep; 2010 Mar; 37(3):1191-5. PubMed ID: 19247800
[TBL] [Abstract][Full Text] [Related]
17. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation.
Nogueira-Machado JA; Volpe CM; Veloso CA; Chaves MM
Expert Opin Ther Targets; 2011 Aug; 15(8):1023-35. PubMed ID: 21585289
[TBL] [Abstract][Full Text] [Related]
18. Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis.
Urbonaviciute V; Meister S; Fürnrohr BG; Frey B; Gückel E; Schett G; Herrmann M; Voll RE
Autoimmunity; 2009 May; 42(4):305-7. PubMed ID: 19811284
[TBL] [Abstract][Full Text] [Related]
19. Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis.
Aslani F; Schuppe HC; Guazzone VA; Bhushan S; Wahle E; Lochnit G; Lustig L; Meinhardt A; Fijak M
Hum Reprod; 2015 Feb; 30(2):417-31. PubMed ID: 25452436
[TBL] [Abstract][Full Text] [Related]
20. Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis.
Li X; Yue Y; Zhu Y; Xiong S
Mol Immunol; 2015 May; 65(1):177-88. PubMed ID: 25660970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
